#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=8. Complications of LVADs
1-1	0-2	8.	_	_	_	_
1-2	3-16	Complications	abstract[1]	new[1]	_	_
1-3	17-19	of	abstract[1]	new[1]	_	_
1-4	20-25	LVADs	abstract[1]|abstract	new[1]|new	coref	5-14

#Text=While survival has improved with CF-LVADS , the adverse event profile remains high .
2-1	26-31	While	_	_	_	_
2-2	32-40	survival	event	new	_	_
2-3	41-44	has	_	_	_	_
2-4	45-53	improved	_	_	_	_
2-5	54-58	with	_	_	_	_
2-6	59-67	CF-LVADS	abstract	new	_	_
2-7	68-69	,	_	_	_	_
2-8	70-73	the	abstract[6]	new[6]	_	_
2-9	74-81	adverse	event[5]|abstract[6]	new[5]|new[6]	_	_
2-10	82-87	event	event[5]|abstract[6]	new[5]|new[6]	_	_
2-11	88-95	profile	abstract[6]	new[6]	_	_
2-12	96-103	remains	_	_	_	_
2-13	104-108	high	_	_	_	_
2-14	109-110	.	_	_	_	_

#Text=At 1 month post-implant , nearly 30 % and at 1 year , almost 80 % of patients , require readmission .
3-1	111-113	At	_	_	_	_
3-2	114-115	1	_	_	_	_
3-3	116-121	month	_	_	_	_
3-4	122-134	post-implant	_	_	_	_
3-5	135-136	,	_	_	_	_
3-6	137-143	nearly	abstract[7]	new[7]	_	_
3-7	144-146	30	abstract[7]	new[7]	_	_
3-8	147-148	%	abstract[7]	new[7]	_	_
3-9	149-152	and	_	_	_	_
3-10	153-155	at	_	_	_	_
3-11	156-157	1	time[8]	new[8]	coref	4-6[13_8]
3-12	158-162	year	time[8]	new[8]	_	_
3-13	163-164	,	_	_	_	_
3-14	165-171	almost	abstract[9]	new[9]	_	_
3-15	172-174	80	abstract[9]	new[9]	_	_
3-16	175-176	%	abstract[9]	new[9]	_	_
3-17	177-179	of	abstract[9]	new[9]	_	_
3-18	180-188	patients	abstract[9]|person	new[9]|new	coref	5-12[18_0]
3-19	189-190	,	_	_	_	_
3-20	191-198	require	_	_	_	_
3-21	199-210	readmission	event	new	_	_
3-22	211-212	.	_	_	_	_

#Text=The common LVAD-related complications , outside of the immediate post-operative period , are outlined in Table 4 .
4-1	213-216	The	abstract[12]	new[12]	coref	6-4[22_12]
4-2	217-223	common	abstract[12]	new[12]	_	_
4-3	224-236	LVAD-related	abstract[12]	new[12]	_	_
4-4	237-250	complications	abstract[12]	new[12]	_	_
4-5	251-252	,	abstract[12]	new[12]	_	_
4-6	253-260	outside	abstract[12]|time[13]	new[12]|giv[13]	_	_
4-7	261-263	of	abstract[12]|time[13]	new[12]|giv[13]	_	_
4-8	264-267	the	abstract[12]|time[13]	new[12]|giv[13]	_	_
4-9	268-277	immediate	abstract[12]|time[13]	new[12]|giv[13]	_	_
4-10	278-292	post-operative	abstract[12]|time[13]	new[12]|giv[13]	_	_
4-11	293-299	period	abstract[12]|time[13]	new[12]|giv[13]	_	_
4-12	300-301	,	_	_	_	_
4-13	302-305	are	_	_	_	_
4-14	306-314	outlined	_	_	_	_
4-15	315-317	in	_	_	_	_
4-16	318-323	Table	abstract[14]	new[14]	_	_
4-17	324-325	4	abstract[14]	new[14]	_	_
4-18	326-327	.	_	_	_	_

#Text=Providers in the community may be the first medical contact for patients with LVADs experiencing a complication .
5-1	328-337	Providers	event[15]	new[15]	coref	5-7[17_15]
5-2	338-340	in	event[15]	new[15]	_	_
5-3	341-344	the	event[15]|organization[16]	new[15]|new[16]	_	_
5-4	345-354	community	event[15]|organization[16]	new[15]|new[16]	_	_
5-5	355-358	may	_	_	_	_
5-6	359-361	be	_	_	_	_
5-7	362-365	the	event[17]	giv[17]	_	_
5-8	366-371	first	event[17]	giv[17]	_	_
5-9	372-379	medical	event[17]	giv[17]	_	_
5-10	380-387	contact	event[17]	giv[17]	_	_
5-11	388-391	for	event[17]	giv[17]	_	_
5-12	392-400	patients	event[17]|person[18]	giv[17]|giv[18]	coref	10-5[45_18]
5-13	401-405	with	event[17]|person[18]	giv[17]|giv[18]	_	_
5-14	406-411	LVADs	event[17]|person[18]|abstract	giv[17]|giv[18]|giv	coref	8-19
5-15	412-424	experiencing	event[17]|person[18]	giv[17]|giv[18]	_	_
5-16	425-426	a	event[17]|person[18]|abstract[20]	giv[17]|giv[18]|new[20]	_	_
5-17	427-439	complication	event[17]|person[18]|abstract[20]	giv[17]|giv[18]|new[20]	_	_
5-18	440-441	.	_	_	_	_

#Text=Though management of these complications should be in concert with LVAD specialists , an awareness and understanding of the common complications can help with timely diagnosis and therapeutic intervention .
6-1	442-448	Though	_	_	_	_
6-2	449-459	management	organization[21]	new[21]	_	_
6-3	460-462	of	organization[21]	new[21]	_	_
6-4	463-468	these	organization[21]|abstract[22]	new[21]|giv[22]	coref	6-19[27_22]
6-5	469-482	complications	organization[21]|abstract[22]	new[21]|giv[22]	_	_
6-6	483-489	should	_	_	_	_
6-7	490-492	be	_	_	_	_
6-8	493-495	in	_	_	_	_
6-9	496-503	concert	_	_	_	_
6-10	504-508	with	_	_	_	_
6-11	509-513	LVAD	abstract|person[24]	new|new[24]	coref	7-2
6-12	514-525	specialists	person[24]	new[24]	_	_
6-13	526-527	,	_	_	_	_
6-14	528-530	an	abstract[25]	new[25]	_	_
6-15	531-540	awareness	abstract[25]	new[25]	_	_
6-16	541-544	and	_	_	_	_
6-17	545-558	understanding	abstract[26]	new[26]	_	_
6-18	559-561	of	abstract[26]	new[26]	_	_
6-19	562-565	the	abstract[26]|abstract[27]	new[26]|giv[27]	_	_
6-20	566-572	common	abstract[26]|abstract[27]	new[26]|giv[27]	_	_
6-21	573-586	complications	abstract[26]|abstract[27]	new[26]|giv[27]	_	_
6-22	587-590	can	_	_	_	_
6-23	591-595	help	_	_	_	_
6-24	596-600	with	_	_	_	_
6-25	601-607	timely	event[28]	new[28]	_	_
6-26	608-617	diagnosis	event[28]	new[28]	_	_
6-27	618-621	and	_	_	_	_
6-28	622-633	therapeutic	event[29]	new[29]	_	_
6-29	634-646	intervention	event[29]	new[29]	_	_
6-30	647-648	.	_	_	_	_

#Text=8.1. LVAD Infections
7-1	649-653	8.1.	_	_	_	_
7-2	654-658	LVAD	abstract|abstract[31]	giv|new[31]	coref|coref	8-13[0_31]|9-4[40_0]
7-3	659-669	Infections	abstract[31]	new[31]	_	_

#Text=Due to the presence of a percutaneous driveline exiting the skin , infections remain the Achilles heel of LVADs .
8-1	670-673	Due	_	_	_	_
8-2	674-676	to	_	_	_	_
8-3	677-680	the	abstract[32]	new[32]	coref	17-29[119_32]
8-4	681-689	presence	abstract[32]	new[32]	_	_
8-5	690-692	of	abstract[32]	new[32]	_	_
8-6	693-694	a	abstract[32]|object[33]	new[32]|new[33]	coref	10-19[49_33]
8-7	695-707	percutaneous	abstract[32]|object[33]	new[32]|new[33]	_	_
8-8	708-717	driveline	abstract[32]|object[33]	new[32]|new[33]	_	_
8-9	718-725	exiting	abstract[32]|object[33]	new[32]|new[33]	_	_
8-10	726-729	the	abstract[32]|object[33]|object[34]	new[32]|new[33]|new[34]	coref	19-4[0_34]
8-11	730-734	skin	abstract[32]|object[33]|object[34]	new[32]|new[33]|new[34]	_	_
8-12	735-736	,	_	_	_	_
8-13	737-747	infections	abstract	giv	coref	10-3[43_0]
8-14	748-754	remain	_	_	_	_
8-15	755-758	the	object[37]	new[37]	_	_
8-16	759-767	Achilles	person|object[37]	new|new[37]	_	_
8-17	768-772	heel	object[37]	new[37]	_	_
8-18	773-775	of	object[37]	new[37]	_	_
8-19	776-781	LVADs	object[37]|abstract	new[37]|giv	_	_
8-20	782-783	.	_	_	_	_

#Text=Recent implantation of the first-in-man totally implantable LVAD aims to minimize this risk .
9-1	784-790	Recent	event[39]	new[39]	_	_
9-2	791-803	implantation	event[39]	new[39]	_	_
9-3	804-806	of	event[39]	new[39]	_	_
9-4	807-810	the	event[39]|abstract[40]	new[39]|giv[40]	coref	10-5[0_40]
9-5	811-823	first-in-man	event[39]|abstract[40]	new[39]|giv[40]	_	_
9-6	824-831	totally	event[39]|abstract[40]	new[39]|giv[40]	_	_
9-7	832-843	implantable	event[39]|abstract[40]	new[39]|giv[40]	_	_
9-8	844-848	LVAD	event[39]|abstract[40]	new[39]|giv[40]	_	_
9-9	849-853	aims	_	_	_	_
9-10	854-856	to	_	_	_	_
9-11	857-865	minimize	_	_	_	_
9-12	866-870	this	abstract[41]	new[41]	coref	13-14[81_41]
9-13	871-875	risk	abstract[41]	new[41]	_	_
9-14	876-877	.	_	_	_	_

#Text=ISHLT classifies infections in LVAD patients as VAD-specific ( involving the pump , cannula , pocket , or percutaneous driveline ) , VAD-related ( infective endocarditis , blood stream infections including central venous catheter associated , mediastinitis ) and non-VAD infections such as pneumonia .
10-1	878-883	ISHLT	organization	new	_	_
10-2	884-894	classifies	_	_	_	_
10-3	895-905	infections	abstract[43]	giv[43]	coref	10-40[54_43]
10-4	906-908	in	abstract[43]	giv[43]	_	_
10-5	909-913	LVAD	abstract[43]|abstract|person[45]	giv[43]|giv|giv[45]	coref|coref	15-24|18-13[129_45]
10-6	914-922	patients	abstract[43]|person[45]	giv[43]|giv[45]	_	_
10-7	923-925	as	_	_	_	_
10-8	926-938	VAD-specific	_	_	_	_
10-9	939-940	(	_	_	_	_
10-10	941-950	involving	_	_	_	_
10-11	951-954	the	object[46]	new[46]	coref	28-4[0_46]
10-12	955-959	pump	object[46]	new[46]	_	_
10-13	960-961	,	_	_	_	_
10-14	962-969	cannula	object	new	_	_
10-15	970-971	,	_	_	_	_
10-16	972-978	pocket	object	new	_	_
10-17	979-980	,	_	_	_	_
10-18	981-983	or	_	_	_	_
10-19	984-996	percutaneous	object[49]	giv[49]	coref	12-4[0_49]
10-20	997-1006	driveline	object[49]	giv[49]	_	_
10-21	1007-1008	)	_	_	_	_
10-22	1009-1010	,	_	_	_	_
10-23	1011-1022	VAD-related	_	_	_	_
10-24	1023-1024	(	_	_	_	_
10-25	1025-1034	infective	_	_	_	_
10-26	1035-1047	endocarditis	_	_	_	_
10-27	1048-1049	,	_	_	_	_
10-28	1050-1055	blood	substance|substance[51]	new|new[51]	coref	14-5
10-29	1056-1062	stream	substance[51]	new[51]	_	_
10-30	1063-1073	infections	_	_	_	_
10-31	1074-1083	including	_	_	_	_
10-32	1084-1091	central	object[52]	new[52]	_	_
10-33	1092-1098	venous	object[52]	new[52]	_	_
10-34	1099-1107	catheter	object[52]	new[52]	_	_
10-35	1108-1118	associated	_	_	_	_
10-36	1119-1120	,	_	_	_	_
10-37	1121-1134	mediastinitis	abstract	new	_	_
10-38	1135-1136	)	_	_	_	_
10-39	1137-1140	and	_	_	_	_
10-40	1141-1148	non-VAD	abstract[54]	giv[54]	coref	18-8[127_54]
10-41	1149-1159	infections	abstract[54]	giv[54]	_	_
10-42	1160-1164	such	abstract[54]	giv[54]	_	_
10-43	1165-1167	as	abstract[54]	giv[54]	_	_
10-44	1168-1177	pneumonia	abstract[54]|abstract	giv[54]|new	_	_
10-45	1178-1179	.	_	_	_	_

#Text=Different techniques , largely limited to single-center experiences , have been shown to reduce infection rates and there is no universal protocol .
11-1	1180-1189	Different	abstract[56]	new[56]	_	_
11-2	1190-1200	techniques	abstract[56]	new[56]	_	_
11-3	1201-1202	,	abstract[56]	new[56]	_	_
11-4	1203-1210	largely	abstract[56]	new[56]	_	_
11-5	1211-1218	limited	abstract[56]	new[56]	_	_
11-6	1219-1221	to	abstract[56]	new[56]	_	_
11-7	1222-1235	single-center	abstract[56]|event[57]	new[56]|new[57]	_	_
11-8	1236-1247	experiences	abstract[56]|event[57]	new[56]|new[57]	_	_
11-9	1248-1249	,	_	_	_	_
11-10	1250-1254	have	_	_	_	_
11-11	1255-1259	been	_	_	_	_
11-12	1260-1265	shown	_	_	_	_
11-13	1266-1268	to	_	_	_	_
11-14	1269-1275	reduce	_	_	_	_
11-15	1276-1285	infection	event|abstract[59]	new|new[59]	coref	12-4[64_0]
11-16	1286-1291	rates	abstract[59]	new[59]	_	_
11-17	1292-1295	and	_	_	_	_
11-18	1296-1301	there	_	_	_	_
11-19	1302-1304	is	_	_	_	_
11-20	1305-1307	no	abstract[60]	new[60]	_	_
11-21	1308-1317	universal	abstract[60]	new[60]	_	_
11-22	1318-1326	protocol	abstract[60]	new[60]	_	_
11-23	1327-1328	.	_	_	_	_

#Text=Risk factors for driveline infection include trauma to the driveline exit site , younger age , higher body mass index and exposed driveline velour .
12-1	1329-1333	Risk	person|abstract[62]	new|new[62]	_	_
12-2	1334-1341	factors	abstract[62]	new[62]	_	_
12-3	1342-1345	for	abstract[62]	new[62]	_	_
12-4	1346-1355	driveline	abstract[62]|object|event[64]	new[62]|giv|giv[64]	coref|coref	12-10|13-17[0_64]
12-5	1356-1365	infection	abstract[62]|event[64]	new[62]|giv[64]	_	_
12-6	1366-1373	include	_	_	_	_
12-7	1374-1380	trauma	event[65]	new[65]	_	_
12-8	1381-1383	to	event[65]	new[65]	_	_
12-9	1384-1387	the	event[65]|place[68]	new[65]|new[68]	coref	13-1[76_68]
12-10	1388-1397	driveline	event[65]|object|place[68]	new[65]|giv|new[68]	coref	12-23
12-11	1398-1402	exit	event[65]|abstract|place[68]	new[65]|new|new[68]	coref	13-2
12-12	1403-1407	site	event[65]|place[68]	new[65]|new[68]	_	_
12-13	1408-1409	,	_	_	_	_
12-14	1410-1417	younger	abstract[69]	new[69]	coref	30-14[0_69]
12-15	1418-1421	age	abstract[69]	new[69]	_	_
12-16	1422-1423	,	_	_	_	_
12-17	1424-1430	higher	abstract[72]	new[72]	_	_
12-18	1431-1435	body	object|abstract[71]|abstract[72]	new|new[71]|new[72]	_	_
12-19	1436-1440	mass	abstract[71]|abstract[72]	new[71]|new[72]	_	_
12-20	1441-1446	index	abstract[72]	new[72]	_	_
12-21	1447-1450	and	_	_	_	_
12-22	1451-1458	exposed	object[74]	new[74]	_	_
12-23	1459-1468	driveline	object|object[74]	giv|new[74]	coref	13-5
12-24	1469-1475	velour	object[74]	new[74]	_	_
12-25	1476-1477	.	_	_	_	_

#Text=Meticulous exit site and driveline care and driveline immobilization are advised to reduce the risk of infection .
13-1	1478-1488	Meticulous	place[76]	giv[76]	coref	15-7[91_76]
13-2	1489-1493	exit	abstract|place[76]	giv|giv[76]	coref	21-8
13-3	1494-1498	site	place[76]	giv[76]	_	_
13-4	1499-1502	and	_	_	_	_
13-5	1503-1512	driveline	object|abstract[78]	giv|new[78]	coref|coref	13-8|15-29[98_78]
13-6	1513-1517	care	abstract[78]	new[78]	_	_
13-7	1518-1521	and	_	_	_	_
13-8	1522-1531	driveline	object|abstract[80]	giv|new[80]	coref	14-1
13-9	1532-1546	immobilization	abstract[80]	new[80]	_	_
13-10	1547-1550	are	_	_	_	_
13-11	1551-1558	advised	_	_	_	_
13-12	1559-1561	to	_	_	_	_
13-13	1562-1568	reduce	_	_	_	_
13-14	1569-1572	the	abstract[81]	giv[81]	_	_
13-15	1573-1577	risk	abstract[81]	giv[81]	_	_
13-16	1578-1580	of	abstract[81]	giv[81]	_	_
13-17	1581-1590	infection	abstract[81]|event	giv[81]|giv	coref	21-18[148_0]
13-18	1591-1592	.	_	_	_	_

#Text=Driveline drainage culture and blood cultures should be obtained , and imaging may be needed as well .
14-1	1593-1602	Driveline	object|event[84]|abstract[85]	giv|new[84]|new[85]	coref|coref|coref	15-7|15-14[94_84]|16-1[105_85]
14-2	1603-1611	drainage	event[84]|abstract[85]	new[84]|new[85]	_	_
14-3	1612-1619	culture	abstract[85]	new[85]	_	_
14-4	1620-1623	and	_	_	_	_
14-5	1624-1629	blood	substance|abstract[87]	giv|new[87]	coref|coref	18-1|18-1[125_87]
14-6	1630-1638	cultures	abstract[87]	new[87]	_	_
14-7	1639-1645	should	_	_	_	_
14-8	1646-1648	be	_	_	_	_
14-9	1649-1657	obtained	_	_	_	_
14-10	1658-1659	,	_	_	_	_
14-11	1660-1663	and	_	_	_	_
14-12	1664-1671	imaging	abstract	new	ana	15-1
14-13	1672-1675	may	_	_	_	_
14-14	1676-1678	be	_	_	_	_
14-15	1679-1685	needed	_	_	_	_
14-16	1686-1688	as	_	_	_	_
14-17	1689-1693	well	_	_	_	_
14-18	1694-1695	.	_	_	_	_

#Text=It is important to note that driveline site assessment and obtaining specimens of the drainage should only be performed by members of the LVAD team ( or designated shared care centers ) in order to limit the number of times and the number of people to whom the driveline is exposed .
15-1	1696-1698	It	abstract	giv	coref	17-14
15-2	1699-1701	is	_	_	_	_
15-3	1702-1711	important	_	_	_	_
15-4	1712-1714	to	_	_	_	_
15-5	1715-1719	note	_	_	_	_
15-6	1720-1724	that	_	_	_	_
15-7	1725-1734	driveline	object|place[91]|event[92]	giv|giv[91]|new[92]	coref|coref	15-48[104_0]|17-7[110_91]
15-8	1735-1739	site	place[91]|event[92]	giv[91]|new[92]	_	_
15-9	1740-1750	assessment	event[92]	new[92]	_	_
15-10	1751-1754	and	_	_	_	_
15-11	1755-1764	obtaining	_	_	_	_
15-12	1765-1774	specimens	object[93]	new[93]	_	_
15-13	1775-1777	of	object[93]	new[93]	_	_
15-14	1778-1781	the	object[93]|event[94]	new[93]|giv[94]	coref	16-3[106_94]
15-15	1782-1790	drainage	object[93]|event[94]	new[93]|giv[94]	_	_
15-16	1791-1797	should	_	_	_	_
15-17	1798-1802	only	_	_	_	_
15-18	1803-1805	be	_	_	_	_
15-19	1806-1815	performed	_	_	_	_
15-20	1816-1818	by	_	_	_	_
15-21	1819-1826	members	person[95]	new[95]	_	_
15-22	1827-1829	of	person[95]	new[95]	_	_
15-23	1830-1833	the	person[95]|organization[97]	new[95]|new[97]	coref	21-26[149_97]
15-24	1834-1838	LVAD	person[95]|abstract|organization[97]	new[95]|giv|new[97]	coref	18-13
15-25	1839-1843	team	person[95]|organization[97]	new[95]|new[97]	_	_
15-26	1844-1845	(	person[95]	new[95]	_	_
15-27	1846-1848	or	person[95]	new[95]	_	_
15-28	1849-1859	designated	person[95]|place[99]	new[95]|new[99]	_	_
15-29	1860-1866	shared	person[95]|abstract[98]|place[99]	new[95]|giv[98]|new[99]	_	_
15-30	1867-1871	care	person[95]|abstract[98]|place[99]	new[95]|giv[98]|new[99]	_	_
15-31	1872-1879	centers	person[95]|place[99]	new[95]|new[99]	_	_
15-32	1880-1881	)	person[95]	new[95]	_	_
15-33	1882-1884	in	_	_	_	_
15-34	1885-1890	order	_	_	_	_
15-35	1891-1893	to	_	_	_	_
15-36	1894-1899	limit	_	_	_	_
15-37	1900-1903	the	abstract[100]	new[100]	_	_
15-38	1904-1910	number	abstract[100]	new[100]	_	_
15-39	1911-1913	of	abstract[100]	new[100]	_	_
15-40	1914-1919	times	abstract[100]|time	new[100]|new	_	_
15-41	1920-1923	and	_	_	_	_
15-42	1924-1927	the	abstract[102]	new[102]	_	_
15-43	1928-1934	number	abstract[102]	new[102]	_	_
15-44	1935-1937	of	abstract[102]	new[102]	_	_
15-45	1938-1944	people	abstract[102]|person[103]	new[102]|new[103]	_	_
15-46	1945-1947	to	abstract[102]|person[103]	new[102]|new[103]	_	_
15-47	1948-1952	whom	abstract[102]|person[103]	new[102]|new[103]	_	_
15-48	1953-1956	the	abstract[102]|person[103]|object[104]	new[102]|new[103]|giv[104]	coref	17-8[0_104]
15-49	1957-1966	driveline	abstract[102]|person[103]|object[104]	new[102]|new[103]|giv[104]	_	_
15-50	1967-1969	is	abstract[102]|person[103]	new[102]|new[103]	_	_
15-51	1970-1977	exposed	abstract[102]|person[103]	new[102]|new[103]	_	_
15-52	1978-1979	.	_	_	_	_

#Text=Culture of any drainage is recommended .
16-1	1980-1987	Culture	abstract[105]	giv[105]	_	_
16-2	1988-1990	of	abstract[105]	giv[105]	_	_
16-3	1991-1994	any	abstract[105]|event[106]	giv[105]|giv[106]	_	_
16-4	1995-2003	drainage	abstract[105]|event[106]	giv[105]|giv[106]	_	_
16-5	2004-2006	is	_	_	_	_
16-6	2007-2018	recommended	_	_	_	_
16-7	2019-2020	.	_	_	_	_

#Text=Abnormal swelling of the region surrounding the driveline site should be assessed by imaging studies ( i.e. , ultrasound , CT scan or PET scan ) to assess the presence , extent , and appearance of any fluid collections .
17-1	2021-2029	Abnormal	event[107]	new[107]	_	_
17-2	2030-2038	swelling	event[107]	new[107]	_	_
17-3	2039-2041	of	event[107]	new[107]	_	_
17-4	2042-2045	the	event[107]|place[108]	new[107]|new[108]	_	_
17-5	2046-2052	region	event[107]|place[108]	new[107]|new[108]	_	_
17-6	2053-2064	surrounding	event[107]|place[108]	new[107]|new[108]	_	_
17-7	2065-2068	the	event[107]|place[108]|place[110]	new[107]|new[108]|giv[110]	coref	21-6[146_110]
17-8	2069-2078	driveline	event[107]|place[108]|object|place[110]	new[107]|new[108]|giv|giv[110]	coref	21-7
17-9	2079-2083	site	event[107]|place[108]|place[110]	new[107]|new[108]|giv[110]	_	_
17-10	2084-2090	should	_	_	_	_
17-11	2091-2093	be	_	_	_	_
17-12	2094-2102	assessed	_	_	_	_
17-13	2103-2105	by	_	_	_	_
17-14	2106-2113	imaging	abstract|event[112]	giv|new[112]	appos|coref	17-17[113_112]|24-7[172_0]
17-15	2114-2121	studies	event[112]	new[112]	_	_
17-16	2122-2123	(	_	_	_	_
17-17	2124-2128	i.e.	event[113]|event[114]	giv[113]|giv[114]	appos|appos	17-17[114_113]|17-21[116_114]
17-18	2129-2130	,	event[113]|event[114]	giv[113]|giv[114]	_	_
17-19	2131-2141	ultrasound	event[113]|event[114]	giv[113]|giv[114]	_	_
17-20	2142-2143	,	event[114]	giv[114]	_	_
17-21	2144-2146	CT	event[114]|abstract|event[116]	giv[114]|new|giv[116]	appos|coref	17-24[118_116]|23-8[162_0]
17-22	2147-2151	scan	event[114]|event[116]	giv[114]|giv[116]	_	_
17-23	2152-2154	or	event[114]	giv[114]	_	_
17-24	2155-2158	PET	event[114]|animal|event[118]	giv[114]|new|giv[118]	coref|coref	24-7|30-1[205_118]
17-25	2159-2163	scan	event[114]|event[118]	giv[114]|giv[118]	_	_
17-26	2164-2165	)	_	_	_	_
17-27	2166-2168	to	_	_	_	_
17-28	2169-2175	assess	_	_	_	_
17-29	2176-2179	the	abstract[119]	giv[119]	_	_
17-30	2180-2188	presence	abstract[119]	giv[119]	_	_
17-31	2189-2190	,	_	_	_	_
17-32	2191-2197	extent	abstract	new	coref	21-15[147_0]
17-33	2198-2199	,	_	_	_	_
17-34	2200-2203	and	_	_	_	_
17-35	2204-2214	appearance	abstract[121]	new[121]	_	_
17-36	2215-2217	of	abstract[121]	new[121]	_	_
17-37	2218-2221	any	abstract[121]|object[123]	new[121]|new[123]	_	_
17-38	2222-2227	fluid	abstract[121]|substance|object[123]	new[121]|new|new[123]	_	_
17-39	2228-2239	collections	abstract[121]|object[123]	new[121]|new[123]	_	_
17-40	2240-2241	.	_	_	_	_

#Text=Blood cultures are important to evaluate for occult bloodstream infections , because LVAD patients may not present with typical signs and symptoms .
18-1	2242-2247	Blood	substance|abstract[125]	giv|giv[125]	_	_
18-2	2248-2256	cultures	abstract[125]	giv[125]	_	_
18-3	2257-2260	are	_	_	_	_
18-4	2261-2270	important	_	_	_	_
18-5	2271-2273	to	_	_	_	_
18-6	2274-2282	evaluate	_	_	_	_
18-7	2283-2286	for	_	_	_	_
18-8	2287-2293	occult	abstract[127]	giv[127]	coref	20-10[141_127]
18-9	2294-2305	bloodstream	substance|abstract[127]	new|giv[127]	coref	33-1
18-10	2306-2316	infections	abstract[127]	giv[127]	_	_
18-11	2317-2318	,	_	_	_	_
18-12	2319-2326	because	_	_	_	_
18-13	2327-2331	LVAD	abstract|person[129]	giv|giv[129]	coref|coref	21-30|23-31[166_129]
18-14	2332-2340	patients	person[129]	giv[129]	_	_
18-15	2341-2344	may	_	_	_	_
18-16	2345-2348	not	_	_	_	_
18-17	2349-2356	present	_	_	_	_
18-18	2357-2361	with	_	_	_	_
18-19	2362-2369	typical	abstract[130]	new[130]	_	_
18-20	2370-2375	signs	abstract[130]	new[130]	_	_
18-21	2376-2379	and	_	_	_	_
18-22	2380-2388	symptoms	abstract	new	_	_
18-23	2389-2390	.	_	_	_	_

#Text=Typical pathogens are skin flora like coagulase-negative Staphylococci and Staphylococcus aureus .
19-1	2391-2398	Typical	plant[132]	new[132]	coref	19-4[134_132]
19-2	2399-2408	pathogens	plant[132]	new[132]	_	_
19-3	2409-2412	are	_	_	_	_
19-4	2413-2417	skin	object|plant[134]	giv|giv[134]	_	_
19-5	2418-2423	flora	plant[134]	giv[134]	_	_
19-6	2424-2428	like	plant[134]	giv[134]	_	_
19-7	2429-2447	coagulase-negative	plant[134]|abstract[135]	giv[134]|new[135]	_	_
19-8	2448-2461	Staphylococci	plant[134]|abstract[135]	giv[134]|new[135]	_	_
19-9	2462-2465	and	plant[134]	giv[134]	_	_
19-10	2466-2480	Staphylococcus	plant[134]|abstract[136]	giv[134]|new[136]	_	_
19-11	2481-2487	aureus	plant[134]|abstract[136]	giv[134]|new[136]	_	_
19-12	2488-2489	.	_	_	_	_

#Text=Gram-negative organisms like Pseudomonas spp. and Enterobacteriaceae , and fungal infections can also occur .
20-1	2490-2503	Gram-negative	animal[137]	new[137]	coref	22-16[157_137]
20-2	2504-2513	organisms	animal[137]	new[137]	_	_
20-3	2514-2518	like	animal[137]	new[137]	_	_
20-4	2519-2530	Pseudomonas	animal[137]|abstract|plant[139]	new[137]|new|new[139]	coref	27-10
20-5	2531-2535	spp.	animal[137]|plant[139]	new[137]|new[139]	_	_
20-6	2536-2539	and	animal[137]	new[137]	_	_
20-7	2540-2558	Enterobacteriaceae	animal[137]|abstract	new[137]|new	_	_
20-8	2559-2560	,	animal[137]	new[137]	_	_
20-9	2561-2564	and	animal[137]	new[137]	_	_
20-10	2565-2571	fungal	animal[137]|abstract[141]	new[137]|giv[141]	coref	22-13[155_141]
20-11	2572-2582	infections	animal[137]|abstract[141]	new[137]|giv[141]	_	_
20-12	2583-2586	can	_	_	_	_
20-13	2587-2591	also	_	_	_	_
20-14	2592-2597	occur	_	_	_	_
20-15	2598-2599	.	_	_	_	_

#Text=Surgical evaluation for debridement of the driveline exit site may be needed depending on the extent of the infection , and should be performed by a surgical team with LVAD experience .
21-1	2600-2608	Surgical	abstract[142]	new[142]	_	_
21-2	2609-2619	evaluation	abstract[142]	new[142]	_	_
21-3	2620-2623	for	abstract[142]	new[142]	_	_
21-4	2624-2635	debridement	abstract[142]|event[143]	new[142]|new[143]	coref	26-16[183_143]
21-5	2636-2638	of	abstract[142]|event[143]	new[142]|new[143]	_	_
21-6	2639-2642	the	abstract[142]|event[143]|place[146]	new[142]|new[143]|giv[146]	_	_
21-7	2643-2652	driveline	abstract[142]|event[143]|object|place[146]	new[142]|new[143]|giv|giv[146]	_	_
21-8	2653-2657	exit	abstract[142]|event[143]|abstract|place[146]	new[142]|new[143]|giv|giv[146]	_	_
21-9	2658-2662	site	abstract[142]|event[143]|place[146]	new[142]|new[143]|giv[146]	_	_
21-10	2663-2666	may	_	_	_	_
21-11	2667-2669	be	_	_	_	_
21-12	2670-2676	needed	_	_	_	_
21-13	2677-2686	depending	_	_	_	_
21-14	2687-2689	on	_	_	_	_
21-15	2690-2693	the	abstract[147]	giv[147]	_	_
21-16	2694-2700	extent	abstract[147]	giv[147]	_	_
21-17	2701-2703	of	abstract[147]	giv[147]	_	_
21-18	2704-2707	the	abstract[147]|event[148]	giv[147]|giv[148]	coref	23-28[165_148]
21-19	2708-2717	infection	abstract[147]|event[148]	giv[147]|giv[148]	_	_
21-20	2718-2719	,	_	_	_	_
21-21	2720-2723	and	_	_	_	_
21-22	2724-2730	should	_	_	_	_
21-23	2731-2733	be	_	_	_	_
21-24	2734-2743	performed	_	_	_	_
21-25	2744-2746	by	_	_	_	_
21-26	2747-2748	a	organization[149]	giv[149]	_	_
21-27	2749-2757	surgical	organization[149]	giv[149]	_	_
21-28	2758-2762	team	organization[149]	giv[149]	_	_
21-29	2763-2767	with	organization[149]	giv[149]	_	_
21-30	2768-2772	LVAD	organization[149]|abstract|abstract[151]	giv[149]|giv|new[151]	coref	30-6
21-31	2773-2783	experience	organization[149]|abstract[151]	giv[149]|new[151]	_	_
21-32	2784-2785	.	_	_	_	_

#Text=Infectious diseases consultation may be needed , particularly in the case of polymicrobial infections or multidrug-resistant organisms .
22-1	2786-2796	Infectious	abstract[152]|abstract[153]	new[152]|new[153]	_	_
22-2	2797-2805	diseases	abstract[152]|abstract[153]	new[152]|new[153]	_	_
22-3	2806-2818	consultation	abstract[153]	new[153]	_	_
22-4	2819-2822	may	_	_	_	_
22-5	2823-2825	be	_	_	_	_
22-6	2826-2832	needed	_	_	_	_
22-7	2833-2834	,	_	_	_	_
22-8	2835-2847	particularly	abstract[154]	new[154]	_	_
22-9	2848-2850	in	abstract[154]	new[154]	_	_
22-10	2851-2854	the	abstract[154]	new[154]	_	_
22-11	2855-2859	case	abstract[154]	new[154]	_	_
22-12	2860-2862	of	abstract[154]	new[154]	_	_
22-13	2863-2876	polymicrobial	abstract[154]|abstract[155]|abstract[156]	new[154]|giv[155]|giv[156]	coref|coref	22-13[156_155]|25-1[176_156]
22-14	2877-2887	infections	abstract[154]|abstract[155]|abstract[156]	new[154]|giv[155]|giv[156]	_	_
22-15	2888-2890	or	abstract[154]|abstract[156]	new[154]|giv[156]	_	_
22-16	2891-2910	multidrug-resistant	abstract[154]|abstract[156]|animal[157]	new[154]|giv[156]|giv[157]	_	_
22-17	2911-2920	organisms	abstract[154]|abstract[156]|animal[157]	new[154]|giv[156]|giv[157]	_	_
22-18	2921-2922	.	_	_	_	_

#Text=If bacteremia or sepsis are present , a chest and abdomen CT , transthoracic and even transesophageal echocardiogram should be obtained to evaluate for the source of the infection ( especially in patients with pacemaker or defibrillator leads ) .
23-1	2923-2925	If	_	_	_	_
23-2	2926-2936	bacteremia	abstract	new	_	_
23-3	2937-2939	or	_	_	_	_
23-4	2940-2946	sepsis	abstract	new	_	_
23-5	2947-2950	are	_	_	_	_
23-6	2951-2958	present	_	_	_	_
23-7	2959-2960	,	_	_	_	_
23-8	2961-2962	a	abstract[162]	giv[162]	_	_
23-9	2963-2968	chest	object|abstract[162]	new|giv[162]	_	_
23-10	2969-2972	and	abstract[162]	giv[162]	_	_
23-11	2973-2980	abdomen	object|abstract[162]	new|giv[162]	_	_
23-12	2981-2983	CT	abstract[162]	giv[162]	_	_
23-13	2984-2985	,	abstract[162]	giv[162]	_	_
23-14	2986-2999	transthoracic	abstract[162]	giv[162]	_	_
23-15	3000-3003	and	_	_	_	_
23-16	3004-3008	even	abstract[163]	new[163]	_	_
23-17	3009-3024	transesophageal	abstract[163]	new[163]	_	_
23-18	3025-3039	echocardiogram	abstract[163]	new[163]	_	_
23-19	3040-3046	should	_	_	_	_
23-20	3047-3049	be	_	_	_	_
23-21	3050-3058	obtained	_	_	_	_
23-22	3059-3061	to	_	_	_	_
23-23	3062-3070	evaluate	_	_	_	_
23-24	3071-3074	for	_	_	_	_
23-25	3075-3078	the	abstract[164]	new[164]	_	_
23-26	3079-3085	source	abstract[164]	new[164]	_	_
23-27	3086-3088	of	abstract[164]	new[164]	_	_
23-28	3089-3092	the	abstract[164]|event[165]	new[164]|giv[165]	coref	27-10[187_165]
23-29	3093-3102	infection	abstract[164]|event[165]	new[164]|giv[165]	_	_
23-30	3103-3104	(	_	_	_	_
23-31	3105-3115	especially	person[166]	giv[166]	coref	29-37[0_166]
23-32	3116-3118	in	person[166]	giv[166]	_	_
23-33	3119-3127	patients	person[166]	giv[166]	_	_
23-34	3128-3132	with	person[166]	giv[166]	_	_
23-35	3133-3142	pacemaker	person[166]|object|abstract[169]	giv[166]|new|new[169]	_	_
23-36	3143-3145	or	person[166]|abstract[169]	giv[166]|new[169]	_	_
23-37	3146-3159	defibrillator	person[166]|abstract|abstract[169]	giv[166]|new|new[169]	_	_
23-38	3160-3165	leads	person[166]|abstract[169]	giv[166]|new[169]	_	_
23-39	3166-3167	)	_	_	_	_
23-40	3168-3169	.	_	_	_	_

#Text=There is an emerging role for PET imaging with F-18 labeled fluoro-2-deoxyglucose .
24-1	3170-3175	There	_	_	_	_
24-2	3176-3178	is	_	_	_	_
24-3	3179-3181	an	abstract[170]	new[170]	coref	28-1[190_170]
24-4	3182-3190	emerging	abstract[170]	new[170]	_	_
24-5	3191-3195	role	abstract[170]	new[170]	_	_
24-6	3196-3199	for	abstract[170]	new[170]	_	_
24-7	3200-3203	PET	abstract[170]|animal|abstract[172]	new[170]|giv|giv[172]	_	_
24-8	3204-3211	imaging	abstract[170]|abstract[172]	new[170]|giv[172]	_	_
24-9	3212-3216	with	abstract[170]|abstract[172]	new[170]|giv[172]	_	_
24-10	3217-3221	F-18	abstract[170]|abstract[172]|object|substance[174]	new[170]|giv[172]|new|new[174]	_	_
24-11	3222-3229	labeled	abstract[170]|abstract[172]|substance[174]	new[170]|giv[172]|new[174]	_	_
24-12	3230-3251	fluoro-2-deoxyglucose	abstract[170]|abstract[172]|substance[174]	new[170]|giv[172]|new[174]	_	_
24-13	3252-3253	.	_	_	_	_

#Text=VAD infections are biofilm-based and difficult to eradicate .
25-1	3254-3257	VAD	object|abstract[176]	new|giv[176]	coref|coref	26-4|26-4[180_176]
25-2	3258-3268	infections	abstract[176]	giv[176]	_	_
25-3	3269-3272	are	_	_	_	_
25-4	3273-3286	biofilm-based	_	_	_	_
25-5	3287-3290	and	_	_	_	_
25-6	3291-3300	difficult	_	_	_	_
25-7	3301-3303	to	_	_	_	_
25-8	3304-3313	eradicate	_	_	_	_
25-9	3314-3315	.	_	_	_	_

#Text=Treatment strategies for VAD infections include intravenous antibiotics followed by oral suppression in tandem with surgical debridement .
26-1	3316-3325	Treatment	person|abstract[178]	new|new[178]	_	_
26-2	3326-3336	strategies	abstract[178]	new[178]	_	_
26-3	3337-3340	for	abstract[178]	new[178]	_	_
26-4	3341-3344	VAD	abstract[178]|object|abstract[180]	new[178]|giv|giv[180]	coref	27-1[0_180]
26-5	3345-3355	infections	abstract[178]|abstract[180]	new[178]|giv[180]	_	_
26-6	3356-3363	include	_	_	_	_
26-7	3364-3375	intravenous	substance[181]	new[181]	_	_
26-8	3376-3387	antibiotics	substance[181]	new[181]	_	_
26-9	3388-3396	followed	substance[181]	new[181]	_	_
26-10	3397-3399	by	substance[181]	new[181]	_	_
26-11	3400-3404	oral	substance[181]|event[182]	new[181]|new[182]	_	_
26-12	3405-3416	suppression	substance[181]|event[182]	new[181]|new[182]	_	_
26-13	3417-3419	in	substance[181]	new[181]	_	_
26-14	3420-3426	tandem	substance[181]	new[181]	_	_
26-15	3427-3431	with	substance[181]	new[181]	_	_
26-16	3432-3440	surgical	substance[181]|event[183]	new[181]|giv[183]	coref	27-7[0_183]
26-17	3441-3452	debridement	substance[181]|event[183]	new[181]|giv[183]	_	_
26-18	3453-3454	.	_	_	_	_

#Text=Infections tend to be recurrent despite debridement , with Pseudomonas infection in particular , showing a lower success rate .
27-1	3455-3465	Infections	abstract	giv	coref	30-6[207_0]
27-2	3466-3470	tend	_	_	_	_
27-3	3471-3473	to	_	_	_	_
27-4	3474-3476	be	_	_	_	_
27-5	3477-3486	recurrent	_	_	_	_
27-6	3487-3494	despite	_	_	_	_
27-7	3495-3506	debridement	event	giv	_	_
27-8	3507-3508	,	_	_	_	_
27-9	3509-3513	with	_	_	_	_
27-10	3514-3525	Pseudomonas	abstract|event[187]	giv|giv[187]	coref	31-9[0_187]
27-11	3526-3535	infection	event[187]	giv[187]	_	_
27-12	3536-3538	in	event[187]	giv[187]	_	_
27-13	3539-3549	particular	event[187]	giv[187]	_	_
27-14	3550-3551	,	_	_	_	_
27-15	3552-3559	showing	_	_	_	_
27-16	3560-3561	a	abstract[189]	new[189]	coref	31-5[214_189]
27-17	3562-3567	lower	abstract[189]	new[189]	_	_
27-18	3568-3575	success	abstract|abstract[189]	new|new[189]	_	_
27-19	3576-3580	rate	abstract[189]	new[189]	_	_
27-20	3581-3582	.	_	_	_	_

#Text=The role of pump exchange is not clearly defined .
28-1	3583-3586	The	abstract[190]	giv[190]	_	_
28-2	3587-3591	role	abstract[190]	giv[190]	_	_
28-3	3592-3594	of	abstract[190]	giv[190]	_	_
28-4	3595-3599	pump	abstract[190]|object|event[192]	giv[190]|giv|new[192]	coref|coref	29-26|29-26[201_192]
28-5	3600-3608	exchange	abstract[190]|event[192]	giv[190]|new[192]	_	_
28-6	3609-3611	is	_	_	_	_
28-7	3612-3615	not	_	_	_	_
28-8	3616-3623	clearly	_	_	_	_
28-9	3624-3631	defined	_	_	_	_
28-10	3632-3633	.	_	_	_	_

#Text=One study noted a particularly poor prognosis with candidemia and concomitant presence of a cardiac-implanted electronic device , and failure to remove the device during pump exchange was associated with poor outcomes in 65 % of patients .
29-1	3634-3637	One	abstract[193]	new[193]	coref	31-1[211_193]
29-2	3638-3643	study	abstract[193]	new[193]	_	_
29-3	3644-3649	noted	_	_	_	_
29-4	3650-3651	a	abstract[194]	new[194]	_	_
29-5	3652-3664	particularly	abstract[194]	new[194]	_	_
29-6	3665-3669	poor	abstract[194]	new[194]	_	_
29-7	3670-3679	prognosis	abstract[194]	new[194]	_	_
29-8	3680-3684	with	abstract[194]	new[194]	_	_
29-9	3685-3695	candidemia	abstract[194]|abstract	new[194]|new	_	_
29-10	3696-3699	and	abstract[194]	new[194]	_	_
29-11	3700-3711	concomitant	abstract[194]|abstract[196]	new[194]|new[196]	_	_
29-12	3712-3720	presence	abstract[194]|abstract[196]	new[194]|new[196]	_	_
29-13	3721-3723	of	abstract[194]|abstract[196]	new[194]|new[196]	_	_
29-14	3724-3725	a	abstract[194]|abstract[196]|object[197]	new[194]|new[196]|new[197]	coref	29-23[199_197]
29-15	3726-3743	cardiac-implanted	abstract[194]|abstract[196]|object[197]	new[194]|new[196]|new[197]	_	_
29-16	3744-3754	electronic	abstract[194]|abstract[196]|object[197]	new[194]|new[196]|new[197]	_	_
29-17	3755-3761	device	abstract[194]|abstract[196]|object[197]	new[194]|new[196]|new[197]	_	_
29-18	3762-3763	,	_	_	_	_
29-19	3764-3767	and	_	_	_	_
29-20	3768-3775	failure	event[198]	new[198]	coref	32-28[231_198]
29-21	3776-3778	to	event[198]	new[198]	_	_
29-22	3779-3785	remove	event[198]	new[198]	_	_
29-23	3786-3789	the	event[198]|object[199]	new[198]|giv[199]	_	_
29-24	3790-3796	device	event[198]|object[199]	new[198]|giv[199]	_	_
29-25	3797-3803	during	event[198]	new[198]	_	_
29-26	3804-3808	pump	event[198]|object|event[201]	new[198]|giv|giv[201]	coref|coref	32-13|32-24[230_201]
29-27	3809-3817	exchange	event[198]|event[201]	new[198]|giv[201]	_	_
29-28	3818-3821	was	_	_	_	_
29-29	3822-3832	associated	_	_	_	_
29-30	3833-3837	with	_	_	_	_
29-31	3838-3842	poor	event[202]	new[202]	coref	34-21[242_202]
29-32	3843-3851	outcomes	event[202]	new[202]	_	_
29-33	3852-3854	in	event[202]	new[202]	_	_
29-34	3855-3857	65	event[202]|person[203]	new[202]|new[203]	_	_
29-35	3858-3859	%	event[202]|person[203]	new[202]|new[203]	_	_
29-36	3860-3862	of	event[202]|person[203]	new[202]|new[203]	_	_
29-37	3863-3871	patients	event[202]|person[203]|person	new[202]|new[203]|giv	coref	31-20[217_0]
29-38	3872-3873	.	_	_	_	_

#Text=Some studies have shown that LVAD infections adversely affect survival after adjusting for age and comorbidities .
30-1	3874-3878	Some	event[205]	giv[205]	_	_
30-2	3879-3886	studies	event[205]	giv[205]	_	_
30-3	3887-3891	have	_	_	_	_
30-4	3892-3897	shown	_	_	_	_
30-5	3898-3902	that	_	_	_	_
30-6	3903-3907	LVAD	abstract|abstract[207]	giv|giv[207]	coref|coref	31-22[0_207]|32-4
30-7	3908-3918	infections	abstract[207]	giv[207]	_	_
30-8	3919-3928	adversely	_	_	_	_
30-9	3929-3935	affect	_	_	_	_
30-10	3936-3944	survival	event	new	_	_
30-11	3945-3950	after	_	_	_	_
30-12	3951-3960	adjusting	_	_	_	_
30-13	3961-3964	for	_	_	_	_
30-14	3965-3968	age	abstract	giv	_	_
30-15	3969-3972	and	_	_	_	_
30-16	3973-3986	comorbidities	abstract	new	_	_
30-17	3987-3988	.	_	_	_	_

#Text=One prospective study showed a 22 % overall infection rate of LVADs and a 5.6-times greater 1-year mortality in patients with infections .
31-1	3989-3992	One	abstract[211]	giv[211]	_	_
31-2	3993-4004	prospective	abstract[211]	giv[211]	_	_
31-3	4005-4010	study	abstract[211]	giv[211]	_	_
31-4	4011-4017	showed	_	_	_	_
31-5	4018-4019	a	abstract[214]	giv[214]	_	_
31-6	4020-4022	22	abstract[212]|abstract[214]	new[212]|giv[214]	_	_
31-7	4023-4024	%	abstract[212]|abstract[214]	new[212]|giv[214]	_	_
31-8	4025-4032	overall	abstract[214]	giv[214]	_	_
31-9	4033-4042	infection	event|abstract[214]	giv|giv[214]	coref	34-8[240_0]
31-10	4043-4047	rate	abstract[214]	giv[214]	_	_
31-11	4048-4050	of	abstract[214]	giv[214]	_	_
31-12	4051-4056	LVADs	abstract[214]|abstract	giv[214]|new	_	_
31-13	4057-4060	and	_	_	_	_
31-14	4061-4062	a	event[216]	new[216]	coref	32-2[0_216]
31-15	4063-4072	5.6-times	event[216]	new[216]	_	_
31-16	4073-4080	greater	event[216]	new[216]	_	_
31-17	4081-4087	1-year	event[216]	new[216]	_	_
31-18	4088-4097	mortality	event[216]	new[216]	_	_
31-19	4098-4100	in	event[216]	new[216]	_	_
31-20	4101-4109	patients	event[216]|person[217]	new[216]|giv[217]	_	_
31-21	4110-4114	with	event[216]|person[217]	new[216]|giv[217]	_	_
31-22	4115-4125	infections	event[216]|person[217]|abstract	new[216]|giv[217]|giv	coref	32-4[221_0]
31-23	4126-4127	.	_	_	_	_

#Text=Besides mortality , LVAD infections are associated with a greater risk of pump thrombosis , bleeding complications , prolonged hospitalization , need for pump exchange , and failure to achieve transplantation .
32-1	4128-4135	Besides	_	_	_	_
32-2	4136-4145	mortality	event	giv	coref	33-12[236_0]
32-3	4146-4147	,	_	_	_	_
32-4	4148-4152	LVAD	abstract|abstract[221]	giv|giv[221]	coref|coref	33-1[234_221]|34-9
32-5	4153-4163	infections	abstract[221]	giv[221]	_	_
32-6	4164-4167	are	_	_	_	_
32-7	4168-4178	associated	_	_	_	_
32-8	4179-4183	with	_	_	_	_
32-9	4184-4185	a	abstract[222]	new[222]	_	_
32-10	4186-4193	greater	abstract[222]	new[222]	_	_
32-11	4194-4198	risk	abstract[222]	new[222]	_	_
32-12	4199-4201	of	abstract[222]	new[222]	_	_
32-13	4202-4206	pump	abstract[222]|object|event[224]	new[222]|giv|new[224]	coref	32-24
32-14	4207-4217	thrombosis	abstract[222]|event[224]	new[222]|new[224]	_	_
32-15	4218-4219	,	abstract[222]	new[222]	_	_
32-16	4220-4228	bleeding	abstract[222]|abstract|abstract[226]	new[222]|new|new[226]	coref	36-6[248_226]
32-17	4229-4242	complications	abstract[222]|abstract[226]	new[222]|new[226]	_	_
32-18	4243-4244	,	abstract[222]	new[222]	_	_
32-19	4245-4254	prolonged	abstract[222]|event[227]	new[222]|new[227]	_	_
32-20	4255-4270	hospitalization	abstract[222]|event[227]	new[222]|new[227]	_	_
32-21	4271-4272	,	abstract[222]	new[222]	_	_
32-22	4273-4277	need	abstract[222]|abstract[228]	new[222]|new[228]	_	_
32-23	4278-4281	for	abstract[222]|abstract[228]	new[222]|new[228]	_	_
32-24	4282-4286	pump	abstract[222]|abstract[228]|object|event[230]	new[222]|new[228]|giv|giv[230]	_	_
32-25	4287-4295	exchange	abstract[222]|abstract[228]|event[230]	new[222]|new[228]|giv[230]	_	_
32-26	4296-4297	,	abstract[222]	new[222]	_	_
32-27	4298-4301	and	abstract[222]	new[222]	_	_
32-28	4302-4309	failure	abstract[222]|event[231]	new[222]|giv[231]	_	_
32-29	4310-4312	to	abstract[222]|event[231]	new[222]|giv[231]	_	_
32-30	4313-4320	achieve	abstract[222]|event[231]	new[222]|giv[231]	_	_
32-31	4321-4336	transplantation	abstract[222]|event[231]|event	new[222]|giv[231]|new	_	_
32-32	4337-4338	.	_	_	_	_

#Text=Bloodstream infections , in particular , are associated with stroke and increased mortality .
33-1	4339-4350	Bloodstream	substance|abstract[234]	giv|giv[234]	_	_
33-2	4351-4361	infections	abstract[234]	giv[234]	_	_
33-3	4362-4363	,	_	_	_	_
33-4	4364-4366	in	_	_	_	_
33-5	4367-4377	particular	_	_	_	_
33-6	4378-4379	,	_	_	_	_
33-7	4380-4383	are	_	_	_	_
33-8	4384-4394	associated	_	_	_	_
33-9	4395-4399	with	_	_	_	_
33-10	4400-4406	stroke	event	new	_	_
33-11	4407-4410	and	_	_	_	_
33-12	4411-4420	increased	event[236]	giv[236]	_	_
33-13	4421-4430	mortality	event[236]	giv[236]	_	_
33-14	4431-4432	.	_	_	_	_

#Text=Despite these risks , the presence of an LVAD infection has not been shown to have a negative impact on post-transplant outcomes .
34-1	4433-4440	Despite	_	_	_	_
34-2	4441-4446	these	abstract[237]	new[237]	_	_
34-3	4447-4452	risks	abstract[237]	new[237]	_	_
34-4	4453-4454	,	_	_	_	_
34-5	4455-4458	the	abstract[238]	new[238]	_	_
34-6	4459-4467	presence	abstract[238]	new[238]	_	_
34-7	4468-4470	of	abstract[238]	new[238]	_	_
34-8	4471-4473	an	abstract[238]|event[240]	new[238]|giv[240]	_	_
34-9	4474-4478	LVAD	abstract[238]|abstract|event[240]	new[238]|giv|giv[240]	coref	36-11
34-10	4479-4488	infection	abstract[238]|event[240]	new[238]|giv[240]	_	_
34-11	4489-4492	has	_	_	_	_
34-12	4493-4496	not	_	_	_	_
34-13	4497-4501	been	_	_	_	_
34-14	4502-4507	shown	_	_	_	_
34-15	4508-4510	to	_	_	_	_
34-16	4511-4515	have	_	_	_	_
34-17	4516-4517	a	abstract[241]	new[241]	_	_
34-18	4518-4526	negative	abstract[241]	new[241]	_	_
34-19	4527-4533	impact	abstract[241]	new[241]	_	_
34-20	4534-4536	on	abstract[241]	new[241]	_	_
34-21	4537-4552	post-transplant	abstract[241]|event[242]	new[241]|giv[242]	_	_
34-22	4553-4561	outcomes	abstract[241]|event[242]	new[241]|giv[242]	_	_
34-23	4562-4563	.	_	_	_	_

#Text=8.2. Gastrointestinal ( GI ) Bleed
35-1	4564-4568	8.2.	_	_	_	_
35-2	4569-4585	Gastrointestinal	person[244]	new[244]	_	_
35-3	4586-4587	(	person[244]	new[244]	_	_
35-4	4588-4590	GI	abstract|person[244]	new|new[244]	coref	36-1
35-5	4591-4592	)	person[244]	new[244]	_	_
35-6	4593-4598	Bleed	person[244]	new[244]	_	_

#Text=GI bleed is one of the most frequent complications after LVAD implant and the most common reason for hospital readmission .
36-1	4599-4601	GI	abstract|event[246]	giv|new[246]	_	_
36-2	4602-4607	bleed	event[246]	new[246]	_	_
36-3	4608-4610	is	_	_	_	_
36-4	4611-4614	one	abstract[247]	new[247]	_	_
36-5	4615-4617	of	abstract[247]	new[247]	_	_
36-6	4618-4621	the	abstract[247]|abstract[248]	new[247]|giv[248]	_	_
36-7	4622-4626	most	abstract[247]|abstract[248]	new[247]|giv[248]	_	_
36-8	4627-4635	frequent	abstract[247]|abstract[248]	new[247]|giv[248]	_	_
36-9	4636-4649	complications	abstract[247]|abstract[248]	new[247]|giv[248]	_	_
36-10	4650-4655	after	abstract[247]|abstract[248]	new[247]|giv[248]	_	_
36-11	4656-4660	LVAD	abstract[247]|abstract[248]|abstract|event[250]	new[247]|giv[248]|giv|new[250]	coref	38-20
36-12	4661-4668	implant	abstract[247]|abstract[248]|event[250]	new[247]|giv[248]|new[250]	_	_
36-13	4669-4672	and	_	_	_	_
36-14	4673-4676	the	abstract[251]	new[251]	ana	37-1[0_251]
36-15	4677-4681	most	abstract[251]	new[251]	_	_
36-16	4682-4688	common	abstract[251]	new[251]	_	_
36-17	4689-4695	reason	abstract[251]	new[251]	_	_
36-18	4696-4699	for	abstract[251]	new[251]	_	_
36-19	4700-4708	hospital	abstract[251]|place|event[253]	new[251]|new|new[253]	_	_
36-20	4709-4720	readmission	abstract[251]|event[253]	new[251]|new[253]	_	_
36-21	4721-4722	.	_	_	_	_

#Text=It is triggered by the use of antiplatelet and anticoagulant therapy .
37-1	4723-4725	It	abstract	giv	_	_
37-2	4726-4728	is	_	_	_	_
37-3	4729-4738	triggered	_	_	_	_
37-4	4739-4741	by	_	_	_	_
37-5	4742-4745	the	event[255]	new[255]	_	_
37-6	4746-4749	use	event[255]	new[255]	_	_
37-7	4750-4752	of	event[255]	new[255]	_	_
37-8	4753-4765	antiplatelet	event[255]|substance|abstract[257]	new[255]|new|new[257]	_	_
37-9	4766-4769	and	event[255]|abstract[257]	new[255]|new[257]	_	_
37-10	4770-4783	anticoagulant	event[255]|abstract[257]	new[255]|new[257]	_	_
37-11	4784-4791	therapy	event[255]|abstract[257]	new[255]|new[257]	_	_
37-12	4792-4793	.	_	_	_	_

#Text=Additionally , CF-LVADs can cause acquired von Willebrand factor deficiency due to the high shear stress imposed by the LVAD motor , resulting in breakdown of large von Willebrand factor multimers .
38-1	4794-4806	Additionally	_	_	_	_
38-2	4807-4808	,	_	_	_	_
38-3	4809-4817	CF-LVADs	abstract	new	_	_
38-4	4818-4821	can	_	_	_	_
38-5	4822-4827	cause	_	_	_	_
38-6	4828-4836	acquired	abstract[261]	new[261]	_	_
38-7	4837-4840	von	abstract[260]|abstract[261]	new[260]|new[261]	coref	38-28[268_260]
38-8	4841-4851	Willebrand	abstract|abstract[260]|abstract[261]	new|new[260]|new[261]	coref	38-29
38-9	4852-4858	factor	abstract[260]|abstract[261]	new[260]|new[261]	_	_
38-10	4859-4869	deficiency	abstract[261]	new[261]	_	_
38-11	4870-4873	due	_	_	_	_
38-12	4874-4876	to	_	_	_	_
38-13	4877-4880	the	abstract[263]	new[263]	_	_
38-14	4881-4885	high	abstract[263]	new[263]	_	_
38-15	4886-4891	shear	place|abstract[263]	new|new[263]	_	_
38-16	4892-4898	stress	abstract[263]	new[263]	_	_
38-17	4899-4906	imposed	abstract[263]	new[263]	_	_
38-18	4907-4909	by	abstract[263]	new[263]	_	_
38-19	4910-4913	the	abstract[263]|object[265]	new[263]|new[265]	_	_
38-20	4914-4918	LVAD	abstract[263]|abstract|object[265]	new[263]|giv|new[265]	_	_
38-21	4919-4924	motor	abstract[263]|object[265]	new[263]|new[265]	_	_
38-22	4925-4926	,	_	_	_	_
38-23	4927-4936	resulting	_	_	_	_
38-24	4937-4939	in	_	_	_	_
38-25	4940-4949	breakdown	event[266]	new[266]	_	_
38-26	4950-4952	of	event[266]	new[266]	_	_
38-27	4953-4958	large	event[266]|abstract[269]	new[266]|new[269]	_	_
38-28	4959-4962	von	event[266]|abstract[268]|abstract[269]	new[266]|giv[268]|new[269]	_	_
38-29	4963-4973	Willebrand	event[266]|abstract|abstract[268]|abstract[269]	new[266]|giv|giv[268]|new[269]	_	_
38-30	4974-4980	factor	event[266]|abstract[268]|abstract[269]	new[266]|giv[268]|new[269]	_	_
38-31	4981-4990	multimers	event[266]|abstract[269]	new[266]|new[269]	_	_
38-32	4991-4992	.	_	_	_	_

#Text=Also , continuous flow physiology and dysregulation of angiogenic factors have been shown to lead to development of arteriovenous malformations ( AVMs ) in the gastrointestinal tract , nasopharynx , brain , and other tissues .
39-1	4993-4997	Also	_	_	_	_
39-2	4998-4999	,	_	_	_	_
39-3	5000-5010	continuous	abstract[271]	new[271]	_	_
39-4	5011-5015	flow	abstract|abstract[271]	new|new[271]	_	_
39-5	5016-5026	physiology	abstract[271]	new[271]	_	_
39-6	5027-5030	and	_	_	_	_
39-7	5031-5044	dysregulation	abstract[272]	new[272]	_	_
39-8	5045-5047	of	abstract[272]	new[272]	_	_
39-9	5048-5058	angiogenic	abstract[272]|abstract[273]	new[272]|new[273]	_	_
39-10	5059-5066	factors	abstract[272]|abstract[273]	new[272]|new[273]	_	_
39-11	5067-5071	have	_	_	_	_
39-12	5072-5076	been	_	_	_	_
39-13	5077-5082	shown	_	_	_	_
39-14	5083-5085	to	_	_	_	_
39-15	5086-5090	lead	_	_	_	_
39-16	5091-5093	to	_	_	_	_
39-17	5094-5105	development	event[274]	new[274]	_	_
39-18	5106-5108	of	event[274]	new[274]	_	_
39-19	5109-5122	arteriovenous	event[274]|event[275]	new[274]|new[275]	_	_
39-20	5123-5136	malformations	event[274]|event[275]	new[274]|new[275]	_	_
39-21	5137-5138	(	event[274]	new[274]	_	_
39-22	5139-5143	AVMs	event[274]|abstract	new[274]|new	_	_
39-23	5144-5145	)	event[274]	new[274]	_	_
39-24	5146-5148	in	event[274]	new[274]	_	_
39-25	5149-5152	the	event[274]|object[277]	new[274]|new[277]	_	_
39-26	5153-5169	gastrointestinal	event[274]|object[277]	new[274]|new[277]	_	_
39-27	5170-5175	tract	event[274]|object[277]	new[274]|new[277]	_	_
39-28	5176-5177	,	event[274]	new[274]	_	_
39-29	5178-5189	nasopharynx	event[274]|abstract	new[274]|new	_	_
39-30	5190-5191	,	event[274]	new[274]	_	_
39-31	5192-5197	brain	event[274]|object	new[274]|new	_	_
39-32	5198-5199	,	event[274]	new[274]	_	_
39-33	5200-5203	and	event[274]	new[274]	_	_
39-34	5204-5209	other	event[274]|object[280]	new[274]|new[280]	_	_
39-35	5210-5217	tissues	event[274]|object[280]	new[274]|new[280]	_	_
39-36	5218-5219	.	_	_	_	_
